[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit ::
Main Menu
Journal Information::
Articles Archive::
Guide for Authors::
For Reviewers::
Ethical Statements::
Site Facilities::
Contact us::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Copyright Policies




Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

:: Volume 11, Issue 2 (Spring 2023) ::
Shefaye Khatam 2023, 11(2): 1-9 Back to browse issues page
Effects of Hydroalcoholic Extract of Malva Sylvestris L. on the Histological Structure of the Brain in a Mice Model of Parkinson's Disease
Mohammad Babaei , Taher Elmi , Ali Kalantari-Hesari *
Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran , a.kalantarihesari@basu.ac.ir
Abstract:   (578 Views)
Introduction: inflammation, oxidative stress, and reduction of cell antioxidant activity are among the most important causes of Parkinson's disease. In traditional medicine, Malva sylvestris L (M. sylvestris) is known as an immune system enhancer and anti-inflammatory compound. In this study, the effect of the hydroalcoholic extract of M. sylvestris on the histological alterations of the mice brain of an experimental model of Parkinson's disease was investigated. Materials and Methods: In the present study, 40 mice were divided into four groups: negative control (recipient of normal saline), drug control (recipient of hydroalcoholic extract of M. sylvestris at a dose of 200 mg/kg), positive control (induced parkinsonism by injection of neurotoxin MPTP at a dose of 25 mg/kg with 24-hour intervals for 4 consecutive days), and finally the treatment group (induced parkinsonism along with a daily intraperitoneal injection of hydroalcoholic extract of M. sylvestris at a dose of 200 mg per kg for 28 days). At the end of the treatment the brain samples were taken, fixed in 4% buffered formalin solution, entered the stages of tissue passage and slices with a thickness of 12 micrometers were prepared. Slices were stained with hematoxylin-eosin and evaluated with tyrosine hydroxylase immunohistochemical staining. Results: The results showed that the number of cell bodies of neurons and astrocytes in the dense part of the substantia nigra significantly decreased in the treatment group compared to the negative control group However, the number of microglial cells significantly increased in this brain region. This was despite the fact that in the treatment group, all the investigated parameters were similar to the negative control group, and no statistically significant difference was observed. Conclusion: It seems that the use of M. sylvestris can play an effective role in reducing the histological changes in the brain of an experimental Parkinson's disease model.
Keywords: Antioxidants, Parkinson Disease, Substantia Nigra, Tyrosine 3-Monooxygenase
Full-Text [PDF 1278 kb]   (387 Downloads)    
Type of Study: Research --- Open Access, CC-BY-NC | Subject: Neuropathology
1. Verkhodanova V, Coler M, Jonkers R, Lowie W. How expertise and language familiarity influence perception of speech of people with Parkinson's disease. Clinical Linguistics & Phonetics. 2022; 36(2-3):165-82. [DOI:10.1080/02699206.2021.2003433]
2. Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders. 2015; 21(10): 1238-42. [DOI:10.1016/j.parkreldis.2015.08.030]
3. Lutz SG, Holmes JD, Ready EA, Jenkins ME, Johnson AM. Clinical presentation of anxiety in Parkinson's disease: a scoping review. OTJR: Occupation, Participation and Health. 2016; 36(3): 134-47. [DOI:10.1177/1539449216661714]
4. Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, et al. Prodromal markers in parkinson's disease: limitations in longitudinal studies and lessons learned. Frontiers in Aging Neuroscience. 2016; 8: 147. [DOI:10.3389/fnagi.2016.00147]
5. Mariani E, Frabetti F, Tarozzi A, Pelleri MC, Pizzetti F, Casadei R. Meta-analysis of parkinson's disease transcriptome data using tram software: whole substantia nigra tissue and single dopamine neuron differential gene expression. PloS One. 2016; 11(9): e0161567. [DOI:10.1371/journal.pone.0161567]
6. Kano M, Takayanagi T, Harada K, Makino K, Ishikawa F. Antioxidative activity of anthocyanins from purple sweet potato, Ipomoera batatas cultivar Ayamurasaki. Bioscience, biotechnology, and biochemistry. 2005; 69(5): 979-88. [DOI:10.1271/bbb.69.979]
7. Gonda R, Tomoda M, Kanari M, Shimizu N, et al. Constituents of the seed of Malva verticillata, VI, Characterization and immunological activities of a novel acidic polysaccharide.Chem Pharm Bull (Tokyo). 1990; 10: 2771-4. [DOI:10.1248/cpb.38.2771]
8. Zargari A. medicinal plants.Tehran: University of Tehran; 2007.
9. Scorrano S, Lazzoi MR, Mergola L, Di Bello MP, Del Sole R, Vasapollo G. Anthocyanins profile by Q-TOF LC/MS in Myrtus communis berries from Salento Area. Food Analytical Methods. 2017; 10: 2404-11. [DOI:10.1007/s12161-017-0813-6]
10. Yeole NB, Sandhya P, Chaudhari PS, Bhujbal PS. Evaluation of Malva sylvestris and Pedalium murex mucilage as suspending agent. International Journal of PharmTech Research. 2010; 2(1): 385-9.
11. Esteves PF, Sato A, Esquibel MA, de Campos-Buzzi F, Meira AV, Cechinel-Filho V. Antinociceptive activity of Malva sylvestris L. Lat Am J Pharm. 2009; 28(3): 454-6.
12. Ghasemi Z, Kiasalari Z, Ebrahimi F, Ansari F, Sharayeli M, Roghani M. Neuroprotective effect of diosgenin in 6-hydroxydopamine-induced model of Parkinsonâ s disease in the rat. Daneshvar Medicine. 2017; 25(2): 87-98.
13. Nikokalam Nazif N, Khosravi M, Ahmadi R, Bananej M, Majd A. The effect of ghrelin hormone on level of tumor necrosis factor alpha and gene expression of cytochrome b and interleukin 10 in substantia nigra in an animal model of Parkinson's disease. Iranian Journal of Physiology and Pharmacology. 2019; 3(1): 63-73.
14. Nikokalam Nazif N, Khosravi M, Ahmadi R, Bananej M, Majd A. Neuroprotective Effect of Quercetin in 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine-Induced Model of Parkinson's Disease. The Neuroscience Journal of Shefaye Khatam. 2019; 8(1):1-10. [DOI:10.29252/shefa.8.1.1]
15. Terohid SF, Mirazi M, Sarihi A. Study of hepatoprotective effect of Malva neglecta L. hydroethanolic leaf extract in male rat induced with carbon tetrachloride. Journal of Cell & Tissue. 2015; 5(1): 31-42.
16. Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC. Nitric oxide: an antioxidant and neuroprotector. Annals of the New York Academy of Sciences. 2002; 962(1): 389-401. [DOI:10.1111/j.1749-6632.2002.tb04083.x]
17. Yarijani ZM, Godini A, Madani SH, Najafi H. Reduction of cisplatin-induced renal and hepatic side effects in rat through antioxidative and anti-inflammatory properties of Malva sylvestris L. extract. Biomedicine & Pharmacotherapy. 2018; 106: 1767-74. [DOI:10.1016/j.biopha.2018.07.115]
18. Mousavi SM, Hashemi SA, Behbudi G, Mazraedoost S, Omidifar N, Gholami A, Chiang WH, Babapoor A, Pynadathu Rumjit N. A review on health benefits of Malva sylvestris L. nutritional compounds for metabolites, antioxidants, and anti-inflammatory, anticancer, and antimicrobial applications. Evidence-Based Complementary and Alternative Medicine. 2021; 1-13. [DOI:10.1155/2021/5548404]
19. Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nature Reviews Neuroscience. 2015; 16(5): 249-63. [DOI:10.1038/nrn3898]
20. Zhang X, Zhang R, Awan MU, Bai J. The Mechanism and Function of Glia in Parkinson's Disease. Frontiers in Cellular Neuroscience. 2022; 16. [DOI:10.3389/fncel.2022.903469]
21. Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nature Reviews Neuroscience. 2014; 15(5): 300-12. [DOI:10.1038/nrn3722]
22. Biondetti E, Santin MD, Valabregue R, Mangone G, Gaurav R, Pyatigorskaya N, et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Brain. 2021; 144: 3114-3125. [DOI:10.1093/brain/awab191]
23. Chen J, Mao K, Yu H, Wen Y, She H, Zhang H, et al. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease. J. Neuroinflammation. 2021; 18: 295. [DOI:10.1186/s12974-021-02349-y]
24. Choi I, Zhang Y, Seegobin SP, Pruvost M, Wang Q, Purtell K, et al. Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun. 2020; 11: 1386. [DOI:10.1038/s41467-020-15119-w]

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Babaei M, Elmi T, Kalantari-Hesari A. Effects of Hydroalcoholic Extract of Malva Sylvestris L. on the Histological Structure of the Brain in a Mice Model of Parkinson's Disease. Shefaye Khatam 2023; 11 (2) :1-9
URL: http://shefayekhatam.ir/article-1-2353-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 2 (Spring 2023) Back to browse issues page
مجله علوم اعصاب شفای خاتم The Neuroscience Journal of Shefaye Khatam
Persian site map - English site map - Created in 0.06 seconds with 45 queries by YEKTAWEB 4624